Testing BBT001 for healthy volunteers and people with eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 65 years.
- Healthy volunteers: no significant health problems. Eczema patients: moderate to severe atopic dermatitis for at least 12 months that hasn't responded well to creams.
- Eczema patients: eczema covering at least 10% of your body, a score of 3 or higher on a doctor's rating scale, and a week-long average itch score of 4 or more before starting the trial.
- Women who can get pregnant must have a negative pregnancy test and use effective birth control. Men must also use effective contraception.
- Non-smoker or smoke no more than 5 cigarettes a day, and avoid alcohol for 24 hours before each study visit.
- No major health issues like diabetes, HIV, hepatitis, weakened immune system, autoimmune disease, cancer, or history of severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.